For common EML4-ALK positive NSCLC, crizotinib, ceritinib or alectinib are recommended as first-line treatment in the NCCN Guidelines.[13] Whether patients harboring complex genomic rearrangements could benefit differently from variant ALK tyrosine kinase inhibitors is unclear. The gene discussed is EML4; the disease is non-small cell lung carcinoma.